WO2001009298A3 - Strategy for carbohydrate-based cancer vaccines - Google Patents

Strategy for carbohydrate-based cancer vaccines Download PDF

Info

Publication number
WO2001009298A3
WO2001009298A3 PCT/CA2000/000886 CA0000886W WO0109298A3 WO 2001009298 A3 WO2001009298 A3 WO 2001009298A3 CA 0000886 W CA0000886 W CA 0000886W WO 0109298 A3 WO0109298 A3 WO 0109298A3
Authority
WO
WIPO (PCT)
Prior art keywords
modified
sialic acid
marker
cells
acid
Prior art date
Application number
PCT/CA2000/000886
Other languages
French (fr)
Other versions
WO2001009298A2 (en
Inventor
Harold J Jennings
Subash Sad
Zhongnu Guo
Tianmin Liu
Qinling Yang
Original Assignee
Ca Nat Research Council
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ca Nat Research Council filed Critical Ca Nat Research Council
Priority to AU64200/00A priority Critical patent/AU6420000A/en
Priority to MXPA02000958A priority patent/MXPA02000958A/en
Priority to EP00951149A priority patent/EP1198244A2/en
Priority to CA002380488A priority patent/CA2380488A1/en
Priority to IL14777600A priority patent/IL147776A0/en
Priority to JP2001514090A priority patent/JP2003506034A/en
Publication of WO2001009298A2 publication Critical patent/WO2001009298A2/en
Publication of WO2001009298A3 publication Critical patent/WO2001009298A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001169—Tumor associated carbohydrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7012—Compounds having a free or esterified carboxyl group attached, directly or through a carbon chain, to a carbon atom of the saccharide radical, e.g. glucuronic acid, neuraminic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7008—Compounds having an amino group directly attached to a carbon atom of the saccharide radical, e.g. D-galactosamine, ranimustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/095—Neisseria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5152—Tumor cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

The sialic acid component of a sialic acid unit-containing cell surface marker characteristic of cancerous mammalian cells, such as α2-8 polysialic acid, is modified, so that cells normally expressing such a marker express instead a modified sialic acid unit-containing cell surface marker which is strongly immunogenic. For example, the present invention enables, in a portion of patient cells which regularly express α2-8 polysialic acid (i.e. various types of cancer cells), the expression of a highly immunogenic surface antigen namely, modified α2-8 polysialic acid. The modification is suitably N-acylation of a precursor of the sialic acid, so that the N-acylated precursor becomes chemically incorporated in the polysialic acid during its intracellular biochemical synthesis. Antibodies specific for the modified antigen, which can be induced using a conjugate of a suitable portion of the modified sialic acid unit-containing marker (such as α2-8 polysialic acid) and a protein, can then be used to eliminate cells which express α2-8 polysialic acid. Vaccines can be prepared utilizing conjugates of the modified sialic acid-containing marker, or utilizing antibodies produced in response to exposure of a suitable subject to the modified sialic acid-containing marker, for managing cancer conditions which involve cancer cells characterized, at least in part, by expression of modified sialic acid unit containing marker.
PCT/CA2000/000886 1999-07-29 2000-07-28 Strategy for carbohydrate-based cancer vaccines WO2001009298A2 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
AU64200/00A AU6420000A (en) 1999-07-29 2000-07-28 Novel strategy for carbohydrate-based therapeutic vaccines
MXPA02000958A MXPA02000958A (en) 1999-07-29 2000-07-28 Strategy for carbohydrate based cancer vaccines.
EP00951149A EP1198244A2 (en) 1999-07-29 2000-07-28 Strategy for carbohydrate-based cancer vaccines
CA002380488A CA2380488A1 (en) 1999-07-29 2000-07-28 Novel strategy for carbohydrate-based therapeutic vaccines
IL14777600A IL147776A0 (en) 1999-07-29 2000-07-28 Process for modifying sialic acid units of cells
JP2001514090A JP2003506034A (en) 1999-07-29 2000-07-28 New strategies for carbohydrate-based therapeutic vaccines

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CA002279134A CA2279134A1 (en) 1999-07-29 1999-07-29 Novel strategy for carbohydrate-based therapeutic vaccines
CA2,279,134 1999-07-29

Publications (2)

Publication Number Publication Date
WO2001009298A2 WO2001009298A2 (en) 2001-02-08
WO2001009298A3 true WO2001009298A3 (en) 2001-08-23

Family

ID=4163882

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CA2000/000886 WO2001009298A2 (en) 1999-07-29 2000-07-28 Strategy for carbohydrate-based cancer vaccines

Country Status (8)

Country Link
EP (1) EP1198244A2 (en)
JP (1) JP2003506034A (en)
AU (1) AU6420000A (en)
CA (1) CA2279134A1 (en)
IL (1) IL147776A0 (en)
MX (1) MXPA02000958A (en)
WO (1) WO2001009298A2 (en)
ZA (1) ZA200200731B (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001278323A1 (en) * 2000-07-28 2002-02-13 National Research Council Of Canada Modified sialic acid vaccines
US20030108574A1 (en) * 2001-08-21 2003-06-12 Jennings Harold J. Carbohydrate-based whole cell cancer vaccines
BRPI0512413A (en) * 2004-06-23 2008-03-04 Childrens Hosp & Res Ct Oak polysaccharide derivatives and uses in inducing an immune response
US8148335B2 (en) 2004-06-23 2012-04-03 Children's Hospital & Research Center Oakland De-N-acetyl sialic acid antigens, antibodies thereto, and methods of use in cancer therapy
CA2634755C (en) * 2005-12-23 2018-03-27 Gregory R. Moe De-n-acetyl sialic acid antigens, antibodies thereto, and methods of use in cancer therapy
US8414899B2 (en) 2006-04-11 2013-04-09 Yeda Research And Development Co. Ltd. Vaccines comprising multimeric HSP60 peptide carriers
US8999954B2 (en) 2007-07-03 2015-04-07 Childern's Hospital & Research Center at Oakland Inhibitors of polysialic acid de-N-acetylase and methods for using the same
AU2008272792B2 (en) 2007-07-03 2014-03-06 Children's Hospital & Research Center At Oakland Oligosialic acid derivatives, methods of manufacture, and immunological uses
CA2692417C (en) 2007-07-03 2017-03-21 Children's Hospital & Research Center At Oakland Polysialic acid derivatives, methods of production, and uses in enhancing cancer antigen production and targeting
US8640245B2 (en) 2010-12-24 2014-01-28 Kaspersky Lab, Zao Optimization of anti-malware processing by automated correction of detection rules

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5811102A (en) * 1995-06-07 1998-09-22 National Research Council Of Canada Modified meningococcal polysaccharide conjugate vaccines

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5102663A (en) * 1988-10-18 1992-04-07 Sloan-Kettering Instutute For Cancer Research Vaccine for stimulating or enhancing production of antibodies against 9-O-acetyl GD3

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5811102A (en) * 1995-06-07 1998-09-22 National Research Council Of Canada Modified meningococcal polysaccharide conjugate vaccines

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
DUBOIS C ET AL: "A monoclonal antibody against Meningococcus group B polysaccharides used to immunocapture and quantify polysialylated NCAM in tissues and biological fluids.", JOURNAL OF IMMUNOLOGICAL METHODS, vol. 181, no. 1, 1995, pages 125 - 135, XP004021063 *
JENNINGS H J ET AL: "Polysialic acid vaccines against meningitidis caused by Neisseria meningitidis and Escherichia coli K1", POLYSIALIC ACID: FROM MICROBES TO MAN, BIRKAÜSER VERLAG, BASEL, 1993, pages 25 - 38, XP002052676 *
LIU T ET AL: "Biochemical engineering of surface alpha2-8 polysialic acid for immunotargeting tumor cells.", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 275, no. 42, 20 October 2000 (2000-10-20), pages 32832 - 32836, XP002159470 *
MARTERSTECK C M ET AL: "Unique alpha 2,8-polysialylated glycoproteins in breast cancer and leukemia cells.", GLYCOBIOLOGY, vol. 6, no. 3, 1996, pages 289 - 301, XP000979486 *
PON R A ET AL: "N-Propionylated group B meningococcal polysaccharide mimics a unique bactericidal capsular epitope in group B Neisseria meningitidis", JOURNAL OF EXPERIMENTAL MEDICINE, vol. 185, no. 11, 2 June 1997 (1997-06-02), pages 1929 - 1938, XP000872535 *

Also Published As

Publication number Publication date
MXPA02000958A (en) 2003-07-21
EP1198244A2 (en) 2002-04-24
AU6420000A (en) 2001-02-19
IL147776A0 (en) 2002-08-14
CA2279134A1 (en) 2001-01-29
WO2001009298A2 (en) 2001-02-08
JP2003506034A (en) 2003-02-18
ZA200200731B (en) 2003-03-26

Similar Documents

Publication Publication Date Title
EA199700143A1 (en) METHOD AND COMPOSITION FOR LIPIDIZATION OF HYDROPHIL MOLECULES
DE69128791T2 (en) MODIFIED ANTIBODIES WITH CONTROLLED CLEARANCE TIME
WO2001009298A3 (en) Strategy for carbohydrate-based cancer vaccines
HUP0004327A3 (en) Fusion proteins containing human papilloma virus (hpv) proteins and immunological fusion partner with t-helper epitopes to the hpv antigen, as well as vaccine formulations for treatment and/or profilaxis of hpv induced lesions
Mahmoud et al. Advanced procedures for labeling of antibodies with quantum dots
NO20064676L (en) Pharmaceutical salts of 3-O- (3'3'-dimethylsuccinyl) betulinic acid
WO2005084390A3 (en) Partially loaded antibodies and methods of their conjugation
ES2177964T3 (en) PROCEDURE OF PRODUCTION OF ACTIVATED T CELLS MARKED SPECIFIC TUMORS AND ITS USE FOR TUMOR TREATMENT.
EP0248887A4 (en) Cell-free t cell antigen receptor and its clinical utilities.
WO2000078778A3 (en) C-pyrazole a2a receptor agonists
BR0214457A (en) Methods for Cancer Treatment
TR200103581T2 (en) The use of antibodies against CD20 in the treatment of graft versus host disease.
TR200001946T2 (en) Vaccine
WO2000078779A3 (en) N-pyrazole a2a receptor agonists
EP1855719A4 (en) Neutralizing monoclonal antibodies against severe acute respiratory syndrome-associated coronavirus
ATE328611T1 (en) MULTIPLE CARBOHYDRATE-CONTAINING GLYCOPEPTIDE ANTIGENS, VACCINES DEVELOPED THEREFROM AND THEIR USE
FI950062A (en) Foroactivation of proteins for conjugation purposes
WO2000025722A3 (en) ENHANCED VACCINES COMPRISING SELF AND NON-SELF IgE PORTIONS OR DIMERIC ANTIGENS
EP1908837A3 (en) Human receptor proteins, related reagents and methods
WO2002009744A3 (en) Modified sialic acid vaccines
Ip et al. Increase in serum and tissue glycosyltransferases and glycosidases in tumor-bearing rats
WO2003055379A3 (en) Method using a surface-selective nonlinear optical technique for imaging of biological samples
TR200102034T2 (en) Using antibodies for anti cancer vaccination
BR0010711A (en) Use of soluble co-stimulatory molecules to enhance immune responses
AU6008800A (en) Preparation of spheres for diagnostic tests

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2000951149

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 64200/00

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 147776

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 516837

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: PA/A/2002/000958

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 2380488

Country of ref document: CA

Ref document number: IN/PCT/2002/00109/DE

Country of ref document: IN

WWP Wipo information: published in national office

Ref document number: 2000951149

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWW Wipo information: withdrawn in national office

Ref document number: 2000951149

Country of ref document: EP